Asset Details
Do you wish to reserve the book?
Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
Do you wish to request the book?
Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
2026
Overview
This study examines gastrointestinal adverse events (GIAEs) associated with tirzepatide using bibliometric and pharmacovigilance analyses.
A bibliometric analysis of Web of Science data identified research trends in tirzepatide-related adverse events, while a pharmacovigilance analysis of FAERS data (Q2 2022-Q2 2024) assessed real-world GIAEs patterns. Disproportionality, time-to-onset, univariate, and comparative analyses were conducted to evaluate reporting odds ratios (RORs), onset timing, and subgroup differences.
Among 110 studies, cardiovascular outcomes predominated as the research focus. FAERS data showed that nausea (27.7%) and diarrhea (12.8%) were the most frequently reported events, whereas eructation and impaired gastric emptying had the highest disproportionality. GIAEs were more common in older adults, males, and patients receiving concomitant medications, and most occurred within 3 months (median onset: 16 days). Tirzepatide had a lower ROR for GIAEs than GLP-1 receptor agonists but a higher ROR than non-GLP-1 drugs, with a greater risk in patients with type 2 diabetes (T2DM) than in those using tirzepatide for weight loss.
Tirzepatide is associated with an increased risk of GIAEs, particularly among patients with T2DM, males, older adults, and those using concomitant medications. FAERS-based real-world evidence complements clinical trial data and highlights the need for individualized patient monitoring and management strategies.
Publisher
Public Library of Science,PLOS,Public Library of Science (PLoS)
Subject
